심혈관 치료제 시장 - 규모, 점유율, 성장률, 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of cardiovascular drugs Market

The global cardiovascular drugs market represents one of the most established and essential segments of the pharmaceutical industry, driven by the growing burden of heart and blood vessel-related disorders worldwide. Cardiovascular diseases (CVDs) remain the leading cause of mortality globally, with conditions such as hypertension, coronary artery disease, arrhythmia, hyperlipidemia, myocardial infarction, and stroke significantly impacting healthcare systems.

Market Size and Forecast

According to Fortune Business Insights, the global cardiovascular drugs market size was valued at USD 61.58 billion in 2025. The market is projected to grow to USD 63.97 billion in 2026 and further reach USD 86.85 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 3.90% during the forecast period (2026-2034).

The steady growth reflects the chronic nature of cardiovascular diseases, long-term drug dependency, increasing disease awareness, and continued innovation in drug development.

Market Overview and Disease Burden

Cardiovascular diseases are disorders of the heart and blood vessels and include life-threatening conditions such as heart attacks and strokes. According to the World Health Organization (WHO), four out of five cardiovascular disease deaths are caused by heart attacks and strokes. Lifestyle factors such as physical inactivity, unhealthy diets, obesity, smoking, diabetes, and high blood pressure continue to accelerate disease prevalence globally.

Individuals at high risk often exhibit elevated blood pressure, cholesterol, blood glucose levels, and obesity, increasing the long-term demand for cardiovascular therapeutics.

Key Market Drivers

One of the primary drivers of the cardiovascular drugs market is increased awareness of cardiovascular health, along with improved diagnosis and treatment rates. In parallel, continuous research and development (R&D) has led to the introduction of advanced and more effective drug therapies.

Blockbuster drugs such as Eliquis (apixaban), developed by Bristol-Myers Squibb Company and Pfizer Inc., have demonstrated superior clinical outcomes in preventing strokes and heart attacks, significantly boosting market revenues. The growing unmet treatment need, especially in aging populations, further supports sustained market growth.

Market Segmentation Analysis

By Drug Type

Based on drug type, the market is segmented into antihypertensive, antihyperlipidemic, anticoagulants, antiplatelet drugs, and others.

The anticoagulants segment dominates the market, accounting for an estimated 50.44% market share in 2026. This dominance is driven by high drug prices, widespread clinical use, and strong sales of leading brands such as Eliquis. The antihypertensive segment holds the second-largest share, although growth is moderated by the widespread availability of generic drugs.

By Disease Indication

By disease indication, the market is segmented into hypertension, hyperlipidemia, coronary artery disease, arrhythmia, and others.

The hypertension segment is anticipated to grow at a significant CAGR, holding a 31.04% share in 2026, supported by its high global prevalence and its role as a major risk factor for heart attacks and strokes.

By Distribution Channel

In terms of distribution, the market is categorized into hospital pharmacies, retail pharmacies, online pharmacies, and others.

The hospital pharmacies segment leads the market, accounting for 46.84% share in 2026, as cardiovascular drugs are often prescribed following hospital-based diagnosis. Online pharmacies are expected to witness the highest growth rate due to increasing digital adoption and convenience.

Regional Analysis

North America dominated the cardiovascular drugs market with a 45.16% share in 2025, generating USD 28.78 billion in revenue in 2026. The U.S. market alone is projected to reach USD 26.68 billion by 2026, driven by high disease prevalence and strong R&D activity.

The Asia Pacific region is expected to witness the fastest growth, with Japan reaching USD 5.31 billion, China USD 3.73 billion, and India USD 1.83 billion by 2026. Europe is also projected to grow steadily due to high cardiovascular mortality rates, particularly in the U.K., France, and Germany.

Competitive Landscape

The market is dominated by major pharmaceutical players such as Bristol-Myers Squibb Company, Pfizer Inc., Bayer AG, Janssen Pharmaceuticals, AstraZeneca, Novartis AG, and Sanofi. The industry remains mature, highly competitive, and strongly influenced by generic drug penetration.

Conclusion

In conclusion, the global cardiovascular drugs market is expected to grow steadily from USD 61.58 billion in 2025 to USD 86.85 billion by 2034, supported by rising cardiovascular disease prevalence, strong demand for anticoagulants, continuous drug innovation, and expanding healthcare access. Despite generic competition, the market will continue to remain a critical pillar of the global pharmaceutical industry due to the chronic and life-threatening nature of cardiovascular diseases.

Segmentation By Drug Type

• Antihypertensive
• Antihyperlipidemic
• Anticoagulants
• Antiplatelet Drugs
• Others

By Disease Indication

• Hypertension
• Hyperlipidemia
• Coronary Artery Disease
• Arrhythmia
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

By Geography

• North America (U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
• Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
• Latin America (Brazil, Mexico, and Rest of Latin America)
• Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Prevalence of Major Cardiovascular Diseases by Key Countries
• 4.2. Pipeline Analysis
• 4.3. Key Industry Developments Such as Mergers & Acquisitions
• 4.4. New Product Launches
• 4.5. The Regulatory Scenario in Key Countries
• 4.6. Reimbursement Scenario by Key Countries
• 4.7. Advances in R&D for Novel Therapeutics

5. Global Cardiovascular Drugs Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Drug Type
  • 5.2.1. Antihypertensive
  • 5.2.2. Antihyperlipidemic
  • 5.2.3. Anticoagulants
  • 5.2.4. Antiplatelet Drugs
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 5.3.1. Hypertension
  • 5.3.2. Hyperlipidemia
  • 5.3.3. Coronary Artery Disease
  • 5.3.4. Arrhythmia
  • 5.3.5. Others
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacies
  • 5.4.2. Retail Pharmacies
  • 5.4.3. Online Pharmacies
  • 5.4.4. Others
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Cardiovascular Drugs Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis - By Drug Type
  • 6.2.1. Antihypertensive
  • 6.2.2. Antihyperlipidemic
  • 6.2.3. Anticoagulants
  • 6.2.4. Antiplatelet Drugs
  • 6.2.5. Others
• 6.3. Market Analysis - By Disease Indication
  • 6.3.1. Hypertension
  • 6.3.2. Hyperlipidemia
  • 6.3.3. Coronary Artery Disease
  • 6.3.4. Arrhythmia
  • 6.3.5. Others
• 6.4. Market Analysis - By Distribution Channel
  • 6.4.1. Hospital Pharmacies
  • 6.4.2. Retail Pharmacies
  • 6.4.3. Online Pharmacies
  • 6.4.4. Others
• 6.5. Market Analysis - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Cardiovascular Drugs Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis - By Drug Type
  • 7.2.1. Antihypertensive
  • 7.2.2. Antihyperlipidemic
  • 7.2.3. Anticoagulants
  • 7.2.4. Antiplatelet Drugs
  • 7.2.5. Others
• 7.3. Market Analysis - By Disease Indication
  • 7.3.1. Hypertension
  • 7.3.2. Hyperlipidemia
  • 7.3.3. Coronary Artery Disease
  • 7.3.4. Arrhythmia
  • 7.3.5. Others
• 7.4. Market Analysis - By Distribution Channel
  • 7.4.1. Hospital Pharmacies
  • 7.4.2. Retail Pharmacies
  • 7.4.3. Online Pharmacies
  • 7.4.4. Others
• 7.5. Market Analysis - By Country/ sub-region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Cardiovascular Drugs Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis - By Drug Type
  • 8.2.1. Antihypertensive
  • 8.2.2. Antihyperlipidemic
  • 8.2.3. Anticoagulants
  • 8.2.4. Antiplatelet Drugs
  • 8.2.5. Others
• 8.3. Market Analysis - By Disease Indication
  • 8.3.1. Hypertension
  • 8.3.2. Hyperlipidemia
  • 8.3.3. Coronary Artery Disease
  • 8.3.4. Arrhythmia
  • 8.3.5. Others
• 8.4. Market Analysis - By Distribution Channel
  • 8.4.1. Hospital Pharmacies
  • 8.4.2. Retail Pharmacies
  • 8.4.3. Online Pharmacies
  • 8.4.4. Others
• 8.5. Market Analysis - By Country/ sub-region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Cardiovascular Drugs Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis - By Drug Type
  • 9.2.1. Antihypertensive
  • 9.2.2. Antihyperlipidemic
  • 9.2.3. Anticoagulants
  • 9.2.4. Antiplatelet Drugs
  • 9.2.5. Others
• 9.3. Market Analysis - By Disease Indication
  • 9.3.1. Hypertension
  • 9.3.2. Hyperlipidemia
  • 9.3.3. Coronary Artery Disease
  • 9.3.4. Arrhythmia
  • 9.3.5. Others
• 9.4. Market Analysis - By Distribution Channel
  • 9.4.1. Hospital Pharmacies
  • 9.4.2. Retail Pharmacies
  • 9.4.3. Online Pharmacies
  • 9.4.4. Others
• 9.5. Market Analysis - By Country/ sub-region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Cardiovascular Drugs Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis - By Drug Type
  • 10.2.1. Antihypertensive
  • 10.2.2. Antihyperlipidemic
  • 10.2.3. Anticoagulants
  • 10.2.4. Antiplatelet Drugs
  • 10.2.5. Others
• 10.3. Market Analysis - By Disease Indication
  • 10.3.1. Hypertension
  • 10.3.2. Hyperlipidemia
  • 10.3.3. Coronary Artery Disease
  • 10.3.4. Arrhythmia
  • 10.3.5. Others
• 10.4. Market Analysis - By Distribution Channel
  • 10.4.1. Hospital Pharmacies
  • 10.4.2. Retail Pharmacies
  • 10.4.3. Online Pharmacies
  • 10.4.4. Others
• 10.5. Market Analysis - By Country/ sub-region
  • 10.5.1. GCC Countries
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2025)
• 11.3. Competition Dashboard
• 11.4. Comparative Analysis - Major Players
• 11.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
  • 11.5.1. Bristol-Myers Squibb Company
    • 11.5.1.1. Overview,
    • 11.5.1.2. Products & services,
    • 11.5.1.3. SWOT analysis,
    • 11.5.1.4. Recent developments,
    • 11.5.1.5. strategies,
    • 11.5.1.6. financials (based on availability)
  • 11.5.2. Pfizer Inc.
    • 11.5.2.1. Overview,
    • 11.5.2.2. Products & services,
    • 11.5.2.3. SWOT analysis,
    • 11.5.2.4. Recent developments,
    • 11.5.2.5. strategies,
    • 11.5.2.6. financials (based on availability)
  • 11.5.3. Bayer AG
    • 11.5.3.1. Overview,
    • 11.5.3.2. Products & services,
    • 11.5.3.3. SWOT analysis,
    • 11.5.3.4. Recent developments,
    • 11.5.3.5. strategies,
    • 11.5.3.6. financials (based on availability)
  • 11.5.4. Janssen Pharmaceuticals, Inc.
    • 11.5.4.1. Overview,
    • 11.5.4.2. Products & services,
    • 11.5.4.3. SWOT analysis,
    • 11.5.4.4. Recent developments,
    • 11.5.4.5. strategies,
    • 11.5.4.6. financials (based on availability)
  • 11.5.5. AstraZeneca
    • 11.5.5.1. Overview,
    • 11.5.5.2. Products & services,
    • 11.5.5.3. SWOT analysis,
    • 11.5.5.4. Recent developments,
    • 11.5.5.5. strategies,
    • 11.5.5.6. financials (based on availability)
  • 11.5.6. Sanofi
    • 11.5.6.1. Overview,
    • 11.5.6.2. Products & services,
    • 11.5.6.3. SWOT analysis,
    • 11.5.6.4. Recent developments,
    • 11.5.6.5. strategies,
    • 11.5.6.6. financials (based on availability)
  • 11.5.7. Novartis AG
    • 11.5.7.1. Overview,
    • 11.5.7.2. Products & services,
    • 11.5.7.3. SWOT analysis,
    • 11.5.7.4. Recent developments,
    • 11.5.7.5. strategies,
    • 11.5.7.6. financials (based on availability)
  • 11.5.8. Merck & Co., Inc.
    • 11.5.8.1. Overview,
    • 11.5.8.2. Products & services,
    • 11.5.8.3. SWOT analysis,
    • 11.5.8.4. Recent developments,
    • 11.5.8.5. strategies,
    • 11.5.8.6. financials (based on availability)
  • 11.5.9. Gilead Sciences, Inc.
    • 11.5.9.1. Overview,
    • 11.5.9.2. Products & services,
    • 11.5.9.3. SWOT analysis,
    • 11.5.9.4. Recent developments,
    • 11.5.9.5. strategies,
    • 11.5.9.6. financials (based on availability)
  • 11.5.10. F. Hoffmann-La Roche Ltd
    • 11.5.10.1. Overview,
    • 11.5.10.2. Products & services,
    • 11.5.10.3. SWOT analysis,
    • 11.5.10.4. Recent developments,
    • 11.5.10.5. strategies,
    • 11.5.10.6. financials (based on availability)
  • 11.5.11. Other Prominent Players
    • 11.5.11.1. Overview,
    • 11.5.11.2. Products & services,
    • 11.5.11.3. SWOT analysis,
    • 11.5.11.4. Recent developments,
    • 11.5.11.5. strategies,
    • 11.5.11.6. financials (based on availability)